Despite recent advances in developing HER-family targeted drugs, clinical trials have shown poor results. Tumour evolution takes place overtime, frequently leading to aberrant new signalling cascades that disrupt the efficacy of targeted therapies and ultimately cause patients to develop resistance against initially effective drugs. To predict outcome and stratify treatment there is an imperative need to develop a systems understanding of concentration-independent parameters that could be monitored in trials and report on tumour evolution. Amongst the circulating tumour markers, exosomes offer a suitable platform for the longitudinal monitoring of protein network signalling in the form of a liquidbiopsy by imaging receptor dimerization status. Here, we illustrate the biomarker utility of monitoring oncogenic receptor signal rewiring using exosomal FRET/FLIM to aid the prediction of clinical outcome and patient treatment stratification.
Introduction
An increasing number of drugs and treatments against cancer have shown high efficacy and promises in vitro with recent technological developments. However, many of these promising agents showing low primary resistance were presented with poor long term results in the clinic due to acquired secondary resistance, leading to inevitable disease relapse and a dramatic reduction of patients' survival. The acquired resistance is one of the main hurdles for the drug treatment efficacy. Recent studies have not only shown high inter-tumour heterogeneity between different patients of the same cancer types, but also significant intratumour heterogeneity within the same patient. This heterogeneity is caused by clonal evolution of the tumour, whereby mutational changes give rise to many different subpopulations of the tumour [1] [2] [3] . This complex and somewhat unpredictable tumour evolution process complicates the efficacy of long term treatment, as resistance easily develops against singletargeted cancer therapies. Moreover, the individual heterogeneity makes the stratification of personalised medicine extremely difficult [4, 5] .Thus, being able to understand and monitor the underlying mechanisms of acquired resistance remains very important for the clinic [6] .
Currently, the clinic mainly uses information obtained from tissue immunohistochemistry combined with imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) for the purpose of prognosis and choosing therapy for the patients. However, with the rise of the -omics era and the continuous emergence of state-of-the-art techniques, there is now more information at the clinicians' disposal to make much better informed decisions. Amongst the many emerging biomarkers, a type of cell-derived extracellular vesicles found in almost all bodily fluids called exosomes have much to offer. They have been implicated by many to play a role in cancer [7] [8] [9] [10] [11] , and they also provide clinicians with a minimally invasive method of obtaining valuable information via liquid biopsy. Cell surface receptors are also found on the surface of exosomes, and many studies have shown the role of these cell surface receptors in acquired resistance [12] [13] [14] [15] [16] .
The focus of this review will be on how resistance is acquired against HER (Human Epidermal growth factor Receptor) family targeted drugs, the role played by the individual receptors and the importance of using HER family receptor dimerization status as a means to track early tumour evolution development. As an example, we show our results in patient cancer tissue samples as previously reported [1] and suggest expanding this approach to patient serum exosomes which have the additional advantage of easily allowing the longitudinal monitoring of the tumour.
The key roles that the HER family play makes them obvious therapeutic targets for anti-cancer therapies. Unsurprisingly, the current standard clinical practice for stratifying cancer patient treatment is based on the expression level of HER family members, depending on the cancer type [17, 26] . To date, all FDA approved cancer therapies in the clinic targeting the HER family members can be divided into 2 classes [3] . First, there are small molecule These drugs have been very effective in many cancers in the clinic, however many patients develop resistance against these therapies often within one year or less [28, 29] .
The principle of all targeted therapies is based on the interruption of pro-oncogenic signalling cascades. However, many of these pathway interventions can be disrupted by cancer-induced changes, resulting in the formation of new, ectopic signalling that favours tumour development. This acquired resistance is known as oncogenic rewiring [30] , and is one of the main reasons for the failure of targeted therapies against the HER family in the clinic [16] .This principle of oncogenic rewiring has led to a successful implementation of anti-HER therapeutic, multi-targeted combination in preclinical cancer models [31] . In clinical trials many cases of initial responders eventually become resistant by developing secondary (or acquired) resistance. Several mechanisms were proposed to explain the oncogenic rewiring of the tumour leading to the acquisition of resistance against HER family targeted therapies.
Mutations in the RTK's extracellular domain could prevent inhibitory binding by targeted mAb therapies while those in the intracellular kinase domain could interfere with TKIs inhibitory functions. Mutations activating downstream effectors of the targeted RTK lead to consistent active signalling despite inhibition of the receptor's kinase activity. Activation of an alternative signalling pathway could lead to a compensatory shift in the dependence of the survival signalling away from the target under therapeutic pressure. All of the above support the existence of an escape mechanism by which tumour can resist and evade targeted therapies.
EGFR, being the target of many clinical drugs, displays oncogenic rewiring through different ways. In lung cancer, EGFR can develop a secondary, acquired T790M mutation, which is commonly found in resistant patients [12] . Besides receptor mutations, there is also aberrant activation of downstream pathways such as MAPK amplification [32] , as well as shifting the pro-oncogenic signalling into other pathways including c-MET [33] .
In colorectal cancer in particular, HER2 activation has been shown to cause acquired resistance against Cetuximab, an EGFR-targeted antibody therapy [34] . This is particularly noteworthy in the process of oncogenic rewiring in the HER family, and has been implicated as a major cause for the development of such resistance as pointed out by several studies [15, 28, 33, 35, 36] . Moreover, HER2 amplification has been suggested to assist the acquisition of resistance against anti-EGFR TKIs [37] . HER3 is known to be a 'pseudokinase' because it lacks a functional intracellular tyrosine kinase domain for intrinsic kinase activity, and is therefore entirely dependent on its heterodimerization partners and ligand binding for all downstream signalling [38] . Known dimerization partners of HER3 include EGFR, HER2, HER4, and c-Met. The pseudokinase HER3 has more tyrosine kinase residues on its intracellular C-terminus than the other HER family members, and is therefore able to directly bind to the PI3K subunit p85 for activation of the PI3K/Akt signalling pathway [17, 38] . In particular, the HER2/3 dimer is known to be the most potent oncogenic activator of the PI3K/Akt pathway [39] . As the key regulator of proliferation, the PI3K/Akt signalling cascade is often found to be activated in drug-resistant tumours [1] , suggesting the highly pivotal role of HER3 in reducing the efficacy of targeted treatments against the HER family. There are many examples of HER3 oncogenic rewiring in the literature. The activation of HER3 signalling by c-Met has been shown to induce resistance against the EGFR TKI Gefitinib in lung cancer, where the Gefitinib-induced inhibition of EGFR-HER3 signalling pathway lead to the prevalence of HER3 activation by c-Met [33] . A different study showed that resistance to erlotinib in lung cancer patients involves HER2/3 feedback loops which stimulated the extracellular signal-regulated kinase (ERK) pathway, induce transcription of HER2 and HER3 and stimulate the interaction between MET and HER3 [31] . The mechanisms of interaction between c-Met, the epidermal growth factor receptor family and other cell surface protein families, how these contribute to signalling crosstalk, oncogenesis, and drug resistance have been excellently reviewed [13] .The compensatory shift from HER2/3 cascade to EGFR/HER3 cascade under the treatment pressure by pertuzumab [40] , alternative HER3 phosphorylation leading to evasion of EFGR and HER2 TKIs [29] , HER3 expression-driven resistance against trastuzumab [14] , the heregulin β1 (HRG)-activated HER3 that leads to resistance against lapatinib [41] .Thus, it is of great clinical interest to detect, prevent, and reverse the aberrant activation of new HER3 signalling cascades which lead to intensified efforts to pharmacologically target it [42] . Despite the increased attention towards this particular member of the HER family, no HER3-targeting drugs have been approved for use to date. The development of anti-HER3 therapies (such as monoclonal anti-HER3 antibody therapy) is still facing difficulties due to a lack of established biomarkers for the stratification of anti-HER3 therapy [43] . It has been suggested that HER3 expression level is not the only important biomarker to be taken into consideration during cancer treatment, but also the interactions of this pseudokinase with the other RTK heterodimerization partners [35] . To measure changes in the heterodimer quantities with treatment and monitor the tumour longitudinally we have developed a FRET/FLIM assay as detailed in the following section.
Dimerization measurement by FRET/FLIM
A significant body of our previous work supported the idea that the HER dimerization status may be more important than HER receptor expression per se in determining sensitivity or resistance to a given therapeutic agent. The extent of HER dimerization between any two receptor pairs could be quantified by Fluorescence Resonance Energy Transfer (FRET) between a pair of suitable FRET fluorophores directly conjugated to the primary antibodies.
FRET is the radiationless transfer of energy between the dipole of a fluorophore called the donor (D) to the dipole of a fluorophore called the acceptor (A). The transfer efficiency depends on the spectral overlap of the fluorescence emission spectrum of the donor with the absorption spectrum of the acceptor, the relative orientation of the two fluorophores and their separation distance. The FRET efficiency varies with the inverse 6 th power of the distance between the donor and acceptor and is typically negligible for distances greater than 10 nm. [44] The spatial scale on which FRET occurs is compatible with the protein dimension which renders FRET as a powerful tool to probe intra-and inter-molecular distances. [45] If one of the HER family members is labelled with a donor conjugated primary antibody and another HER receptor is labelled with an acceptor conjugated primary antibody, the detection of FRET yields proximity information interpreted as heterodimerization.
To identify and quantify FRET we used Fluorescence Lifetime Imaging Microscopy FLIM can be based on various optical and electronic principles. [48] We have developed a custom-built inverted microscope system operating in the single-photon excitation regime as described elsewhere [49] .The FLIM images were analysed to produce distinct lifetimes or a distribution of lifetimes across the image depending on the number of collected photons and the exponential model used. The donor fluorescence was fit to a multiexponential decay using in-house written software (TRI2) utilising a Levenberg-Marquardt algorithm. Pseudo-colour fluorescence lifetime maps were also produced using TRI2.
Previously, we applied our FRET/FLIM technique to assess various HER receptor dimerization in different cancer cell models, xenografts, FFPE tissues and recently to circulating exosomes from cells, xenograft models and patients as detailed in the next section.
We have shown in MCF7 breast cancer cells that erlotinib and gefitinib, but not lapatinib induce EGFR homodimerization [50] . Also, we have demonstrated in the same cell model the existence of EGFR-HER4 dimers and their importance to cell motility [51] . In Hcc1954 breast cancer cells we have shown that gefitinib treatment leads to enhanced EGFR homodimerization [52] . Finally, our aim was to apply this assay to tumour samples in order to assess the prognostic significance and predictive value of HER receptor dimerization in various cancers. In the first clinical application of this technique we quantified EGFR-HER3 dimerization in FFPE tissues from basal-like breast cancer patients treated with a neoadjuvant anti-EGFR treatment (cetuximab or patritumab) and suggested that increased HER3 expression and HER3 activation may mediate residual tumour growth after EGFR-targeted therapy [1] . Figure 1 shows an illustration of the tumour microenvironment ( Fig. 1A ) and the labelling scheme used to detect EGFR-HER3 FRET (Fig. 2B) . The EGFR and HER3 receptors were labelled with fluorescently conjugated cytoplasmic primary antibodies Alexa 546 F4 Another example is the HER2-HER3 dimer which has been shown to drive proliferation and tumour progression. Targeting of this dimer with pertuzumab alongside chemotherapy and trastuzumab, has shown significant clinical utility. By quantifying the HER2-HER3 dimer in 131 formalin fixed paraffin embedded (FFPE) breast cancer tissue microarrays from METABRIC patients we found that the extent of HER2-HER3 dimer formation predicts the 
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Time  attractive to longitudinally monitor patient response to therapy. Molecular analyses similar to those in human tissues may be possible on a new type of liquid biopsy for solid tumours based on analysing exosomes in the patients' blood.
Circulating exosomes
Back in 2014, Ng and Beck proposed an alternative approach for personalised cancer medicinethe "C2c (cancer to chronic disease)" approach [55] . Their proposal was to convert current cancer treatments into regimens throughout the disease progression that mimic manageable chronic diseases in the clinic, by combining different state-of-the-art tools and strategies taken from multiple disciplines (physics, biology, and medicine). A key part of C2c were observed, then confirmed in 1985, and finally termed 'exosomes' in 1987 [9, 11] . Tumours are also known to secret EVs, including exosomes. However it must be noted that the amount and content of these EVs and exosomes varies between different types of cancers, therefore the concentration of tumour exosomes in any given amount of patient serum is not known [7, 11] .Exosomes are unique in the way that they affect other cells. Even before the term 'exosome' was coined, Poutsiaka et al had already demonstrated that melanoma MVBs are capable of activation of immune cells and interfere with immune response [57] . Wolfers et al demonstrated that exosomes can present tumour antigens to dendritic cells to activate antitumour response [11] .The immunogenic effects of tumour-derived exosomes were later demonstrated by others in-vivo [7, 8, 58] .In vitro studies have shown many pro-tumourigenic functions of these tumour derived exosomes, such as their interactions with local and distant microenvironments (such as the stroma) to increase cell motility, promote migration and metastasis [10, [59] [60] [61] [62] [63] , as well as proangiogenic effects upon interactions with endothelial [64, 65] . All these are possible because of their specific biogenesis pathway, which allows the vesicular contents as well as receptors found on the vesicular surface to remain functionally (Fig. 2 ). Fig. 2a shows the time-resolved intensity image and the corresponding donor lifetime pseudocolored map of circulating exosomes. Exosomes were extracted from mice serum using an optimized repeated centrifugation protocol as previously published and imaged after simple adsorption to a glass surface [9] . The receptors of interest were labelled with extracellular Anti-EGFR-IgG-Alexa 546 and Anti-HER3-IgG-Cy5. Fig. 2b shows the As pointed out by Beck and Ng [55] , liquid biopsy is imperative for the C2c approach in the management of cancer. When serology-based -omics are used alongside imaging, the combined sensitivities and specificities of molecular imaging and next-generation sequencing techniques will be able to facilitate early detection of the treatment-resistant variants that evolve as a mechanism of acquired resistance. Examples of other biomarkers are prostatespecific antigen as exemplar protein biomarker, and 2-hydroxyglutarate as an example of epigenetic oncometabolite. By tracking liquid biopsies, clinicians will be able to monitor the ever-evolving -omics heterogeneity of the cancer, which in turn informs the next best treatment(s) as soon as any tumour evolution occurs. The ability to measure receptor status in circulating exosomes allows for the continual monitoring of cancer evolution in the long term. This is something that cannot be done by non-invasive imaging or biopsy, and thus makes a potentially valuable and novel tool that adds to the C2c approach.
Conclusions
It had long been observed that different cancers utilise different mechanisms to rewire their signalling cascades, which leads to resistance development against cancer therapies [35] . In order to improve current prognosis, outcome prediction, and long term efficacy of treatments in the clinic, it is important to gain an in-depth understanding of the underlying mechanisms of signalling rewiring that regulate drug resistance.
The initial exosomal measurement of receptor status at diagnosis will help making decisions on patient treatment, as an added parameter to other biomarkers [53] . The ability to measure receptor status in circulating exosomes also allows the continual monitoring of cancer evolution in the long term. Upon identification of oncogenic rewiring, via FRET/FLIM observation in changes of receptor dimerization status, clinics can use this information to adjust the treatment used for each individual patient. Strategies include designing combinational and/or adjuvant therapies to supress the newly rewired signally cascades, or in some cases even changing the whole regimen altogether to counteract any observed oncogenic rewiring in the individual. As suggested by many and demonstrated by some studies, this combinatorial targeted approaches have very positive outcome in suppression of the rewired resistances [16, 33, 35, 53, 67, 68] .This longitudinal monitoring of receptor dimerisation sheds light on the potential of C2c approach to personalized medicine. Taken together, FLIM histology and exosomal FLIM can be combined to form a powerful tool for monitoring receptor signal rewiring to predict clinical outcome as well as to stratify treatment.
The ultimate objective is to use protein network rewiring information to stratify and guide future therapies that can overcome primary or acquired resistance and either turn cancer into a chronic disease or achieve cure.
With rising interest in exosomes as a platform, receptor dimers as a biomarker, and exosomal FRET/FLIM as a potential tool, many ongoing studies and clinical trials in different cancersincluding colorectal [69] , breast [70] , lung [71] , head and neck [72] , and more -are all producing data that are compiling and contributing to bringing different aspects of this into clinic. Whilst still a long way from completion, the C2c approach of combining biology, physics and medicine to stratify and personalise cancer medicine will take a major step forward with the addition of this new tool.
